GKV Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

GKV Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.86M	Buy	5,761 +1,344	+30%	+$596K	0.92%	34
2026 Q1	$1.97M	Buy	4,417 +112	+3%	+$52.2K	0.74%	41
2025 Q4	$1.95M	Buy	4,305 +100	+2%	+$43.1K	0.73%	40
2025 Q3	$1.65M	Buy	4,205 +177	+4%	+$74K	0.65%	40
2025 Q2	$1.79M	Buy	4,028 +100	+3%	+$46.1K	0.79%	34
2025 Q1	$1.9M	Buy	3,928 +190	+5%	+$88.5K	0.95%	31
2024 Q4	$1.51M	Buy	+3,738	New	+$1.73M	0.61%	43

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GKV Capital Management's VRTX Position: Q2 2026 in Review

GKV Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q2 2026, buying an estimated $596K and bringing the position to 5,761 shares worth $2.86M. The position accounts for 0.92% of the portfolio, ranked #34.

GKV Capital Management first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

GKV Capital Management held 5,761 shares of Vertex Pharmaceuticals worth $2.86M as of Q2 2026.
GKV Capital Management bought 1,344 Vertex Pharmaceuticals shares in Q2 2026, an estimated $596K.
Vertex Pharmaceuticals made up 0.92% of GKV Capital Management's portfolio in Q2 2026, its #34 holding.
GKV Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GKV Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.